{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:30:53Z","timestamp":1786336253158,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Psoriasis is a chronic immune-mediated inflammatory disorder increasingly recognized as a systemic disease rather than an isolated cutaneous condition. In addition to its dermatologic burden, psoriasis is associated with multiple metabolic comorbidities, among which type 2 diabetes mellitus (T2DM) is particularly important because of its prevalence, long-term complications, and potential bidirectional relationship with psoriatic inflammation. Epidemiologic studies consistently suggest that patients with psoriasis, especially those with moderate-to-severe or longstanding disease, have a higher prevalence and incidence of T2DM than the general population. Conversely, metabolic dysfunction, particularly insulin resistance and obesity-related inflammation, may contribute to psoriasis onset and severity. Shared pathogenic pathways include chronic systemic inflammation, dysregulated adipokines, endothelial dysfunction, oxidative stress, and overlapping genetic susceptibility. These mechanistic links have important clinical implications for screening, cardiovascular risk assessment, and therapeutic decision-making. Emerging evidence also suggests that some antidiabetic agents and biologic therapies may influence both metabolic and dermatologic outcomes, although current interventional evidence remains limited and heterogeneous. This narrative review summarizes the epidemiologic evidence supporting the psoriasis\u2013T2DM association, examines shared inflammatory and metabolic mechanisms, and discusses the clinical and therapeutic implications of this comorbidity. Recognizing psoriasis as a systemic inflammatory disease with substantial metabolic consequences may support earlier risk stratification, multidisciplinary care, and more individualized treatment strategies.<\/jats:p>","DOI":"10.3389\/fmed.2026.1897186","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:21:35Z","timestamp":1786335695000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Psoriasis and type 2 diabetes mellitus: epidemiology, shared mechanisms, and therapeutic implications: a narrative review"],"prefix":"10.3389","volume":"13","author":[{"given":"Amr","family":"Molla","sequence":"first","affiliation":[{"name":"Department of Medicine, College of Medicine, Taibah University","place":["Madinah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J Invest Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/s0190-9622(85)70188-0","article-title":"Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris","volume":"13","author":"Henseler","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/bjd.12473","article-title":"Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"169","author":"Coto-Segura","year":"2013","journal-title":"Br J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/2013.jamadermatol.406","article-title":"Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.dsx.2019.01.009","article-title":"The association between psoriasis and diabetes mellitus: a systematic review and meta-analysis","volume":"13","author":"Mamizadeh","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"ref9","volume-title":"IDF Diabetes Atlas","year":"2021"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40257-024-00857-0","article-title":"Managing the patient with psoriasis and metabolic comorbidities","volume":"25","author":"Bellinato","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/archdermatol.2009.48","article-title":"Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses","volume":"145","author":"Qureshi","year":"2009","journal-title":"Arch Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/jid.2011.319","article-title":"Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study","volume":"132","author":"Li","year":"2012","journal-title":"J Invest Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.2337\/dc12-2330","article-title":"Psoriasis and new-onset diabetes: a Danish nationwide cohort study","volume":"36","author":"Khalid","year":"2013","journal-title":"Diabetes Care"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jaad.2013.11.023","article-title":"Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study","volume":"70","author":"Lee","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaad.2017.10.050","article-title":"Psoriasis and the risk of diabetes: a prospective population-based cohort study","volume":"78","author":"Wan","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/PTT.S159163","article-title":"Type 2 diabetes and psoriasis: links and risks","volume":"9","author":"Holm","year":"2019","journal-title":"Psoriasis (Auckl)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.2147\/DMSO.S273147","article-title":"Diabetes and psoriasis: different sides of the same prism","volume":"13","author":"Abramczyk","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jid.2020.11.025","article-title":"Causal relationship and shared genetic loci between psoriasis and type 2 diabetes through trans-disease meta-analysis","volume":"141","author":"Patrick","year":"2021","journal-title":"J Invest Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur Heart J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.3390\/ijms23084457","article-title":"Psoriasis and systemic inflammatory disorders","volume":"23","author":"Tashiro","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/j.diabres.2014.04.009","article-title":"No association between psoriasis and diabetes in the U.S. population","volume":"104","author":"Casagrande","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14744\/nci.2016.16023","article-title":"A brief summary of clinical types of psoriasis","volume":"3","author":"Sarac","year":"2016","journal-title":"North Clin Istanb"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"649408","DOI":"10.3389\/fmed.2021.649408","article-title":"Cutaneous and systemic psoriasis: classifications and classification for the distinction","volume":"8","author":"Yan","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"605691","DOI":"10.3389\/fmed.2021.605691","article-title":"Psoriasis and diabetes, a dangerous association: evaluation of insulin resistance, lipid abnormalities, and cardiovascular risk biomarkers","volume":"8","author":"Brazzelli","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The \u2018psoriatic march\u2019: a concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke","year":"2011","journal-title":"Exp Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-wide scan reveals association of psoriasis with IL-23 and NF-\u03baB pathways","volume":"41","author":"Nair","year":"2009","journal-title":"Nat Genet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.23736\/S0026-4806.24.09570-3","article-title":"Psoriasis and diabetes: a review of the pathophysiological and therapeutic interconnections","volume":"116","author":"De Luca","year":"2025","journal-title":"Minerva Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.4239\/wjd.v12.i8.1141","article-title":"Clinical effects of antidiabetic drugs on psoriasis: the perspective of evidence-based medicine","volume":"12","author":"Zhang","year":"2021","journal-title":"World J Diabetes"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/PTT.S485061","article-title":"Impact of Glp-1 receptor agonists on psoriasis and cardiovascular comorbidities: a narrative review","volume":"14","author":"Haran","year":"2024","journal-title":"Psoriasis (Auckl)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e70177","DOI":"10.1111\/cts.70177","article-title":"Psoriasis risk is lower in type 2 diabetes patients using dipeptidyl peptidase-4 inhibitors or thiazolidinediones compared to sulfonylureas","volume":"18","author":"Chen","year":"2025","journal-title":"Clin Transl Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s13555-024-01327-5","article-title":"Biologic therapy and cardiometabolic risk in psoriasis: a retrospective review","volume":"15","author":"Smith","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jaad.2008.12.012","article-title":"Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis","volume":"60","author":"Cheung","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"ref34","first-page":"297","article-title":"Metabolic comorbidities and psoriasis","volume":"18","author":"Gisondi","year":"2010","journal-title":"Acta Dermatovenerol Croat"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1897186\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:21:36Z","timestamp":1786335696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1897186\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":34,"alternative-id":["10.3389\/fmed.2026.1897186"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1897186","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1897186"}}